{
  "id": "mhgap#risk_safety_783109b0",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "disorders: a systematic review. Drug 16 October 2023). Alcohol Depend. 2019;201:227–35 (https://doi. org/10.1016/j.drugalcdep.2019.03.031). 126 References 186. Maguire MJ, Jackson CF, Marson AG, Nevitt 195. Kishi T, Matsuda Y, Sakuma K, Okuya M, Mishima SJ. Treatments for the prevention of sudden K, Iwata N. Recurrence rates in stable bipolar unexpected death in epilepsy (SUDEP). Cochrane disorder patients after drug discontinuation v. Database Syst Rev. 2020;(4):CD011792. drug maintenance: a systematic review and meta- analysis. Psychol Med. 2021;51(15):2721–9 (https:// 187. Sveinsson O, Andersson T, Carlsson S, Tomson T. doi.org/10.1017/S0033291720003505). The incidence of SUDEP: a nationwide population- based cohort study. Neurology. 2017;89(2):170–7 196. Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya (https://doi.org/10.1212/WNL.0000000000004094). M, Mishima K et al. Mood stabilizers and/ or antipsychotics for bipolar disorder in the 188. Kløvgaard M, Sabers A, Ryvlin P. Update on maintenance phase: a systematic review and sudden unexpected death in epilepsy. Neurol network meta-analysis of randomized controlled Clin. 2022;40(4):741–54 (https://doi.org/10.1016/j. trials. Mol Psychiatry. 2021;26(8):4146–57 (https:// ncl.2022.06.001). doi.org/10.1038/s41380-020-00946-6). 189. Langan Y, Nashef L, Sander JW. Case-control study 197. Kishimoto T, Hagi K, Kurokawa S, Kane JM, of SUDEP. Neurology. 2005;64(7):1131–3 (https:// Correll CU. Long-acting injectable versus oral doi.org/10.1212/01.WNL.0000156352.61328.CB). antipsychotics for the maintenance treatment 190. Cheng ST, Zhang F. A comprehensive meta-review of schizophrenia: a systematic review and of systematic reviews and meta-analyses on comparative meta-analysis of randomised, nonpharmacological interventions for informal cohort, and pre–post studies. Lancet Psychiatry. dementia caregivers. BMC Geriatr. 2020;20(1):137 2021;8(5):387–404 (https://doi.org/10.1016/S2215- (https://doi.org/10.1186/s12877-020-01547-2). 0366(21)00039-0). 191. Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy 198. Schneider-Thoma J, Chalkou K, Dörries C, Bighelli M, Komossa K et al. Maintenance treatment with I, Ceraso A, Huhn M et al. Comparative efficacy and antipsychotic drugs for schizophrenia. Cochrane tolerability of 32 oral and long-acting injectable Database Syst Rev. 2020;(8):CD008016. antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic 192. Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis review and network meta-analysis. Lancet. D, Helfer B et al. Sixty years of placebo-controlled 2022;399(10327):824–36 (https://doi.org/10.1016/ antipsychotic drug trials in acute schizophrenia: S0140-6736(21)01997-8). systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J 199. Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Psychiatry. 2017;174(10):927–42 (https://doi. Bighelli I, Chaimani A et al. Efficacy, acceptability, org/10.1176/appi.ajp.2017.16121358). and tolerability of antipsychotics in children and adolescents with schizophrenia: a network 193. Schneider-Thoma J, Efthimiou O, Huhn M, Krause meta-analysis. Eur Neuropsychopharmacol. M, Reichelt L, Röder H et al. Second-generation 2018;28(6):659–74 (https://doi.org/10.1016/j. antipsychotic drugs and short-term mortality: euroneuro.2018.03.008). a systematic review and meta-analysis of placebo-controlled randomised controlled trials. 200. DelBello MP, Kadakia A, Heller V, Singh R, Hagi K, Lancet Psychiatry. 2018;5(8):653–63 (https://doi. Nosaka T et al. Systematic review and network org/10.1016/S2215-0366(18)30177-9). meta-analysis: efficacy and safety of second- generation antipsychotics in youths with bipolar 194. Kishi T, Ikuta T, Matsui Y, Inada K, Matsuda Y, depression. J Am Acad Child Adolesc Psychiatry. Mishima K et al. Effect of discontinuation v. 2022;61(2):243–54 (https://doi.org/10.1016/j. maintenance of antipsychotic medication on jaac.2021.03.021). relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis. Psychol Med. 2019;49(5):772–9 (https://doi.org/10.1017/ S0033291718001393). 127",
  "gloss_vi": "Disorders: a systematic review. drug 16 october 2023).",
  "source": "WHO mhGAP-IG 2023",
  "url": "https://www.who.int/",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety",
      "referral",
      "management",
      "caregiver"
    ],
    "life_topics": [
      "study",
      "work"
    ],
    "advice_section": [],
    "audience": [],
    "risk_band": "low"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn disorders: a systematic review. Drug 16 October 2023). Alcohol Depend. 2019;201:227–35 (https://doi. org/10.1016/j.drugalcdep.2019.03.031). 126 References 186. Maguire MJ, Jackson CF, Marson AG, Nevitt 195. Kishi T, Matsuda Y, Sakuma K, Okuya M, Mishima SJ. Treatments for the prevention of sudden K, Iwata N. Recurrence rates in stable bipolar unexpected death in epilepsy (SUDEP). Cochrane disorder patients after drug discontinuation v. Database Syst Rev. 2020;(4):CD011792. drug maintenance: a systematic review and meta- analysis. Psychol Med. 2021;51(15):2721–9 (https:// 187. Sveinsson O, Andersson T, Carlsson S, Tomson T. doi.org/10.1017/S0033291720003505). The incidence of SUDEP: a nationwide population- based cohort study. Neurology. 2017;89(2):170–7 196. Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya (https://doi.org/10.1212/WNL.0000000000004094). M, Mishima K et al. Mood stabilizers and/ or antipsychotics for bipolar disorder in the 188. Kløvgaard M, Sabers A, Ryvlin P. Update on maintenance phase: a systematic review and sudden unexpected death in epilepsy. Neurol network meta-analysis of randomized controlled Clin. 2022;40(4):741–54 (https://doi.org/10.1016/j. trials. Mol Psychiatry. 2021;26(8):4146–57 (https:// ncl.2022.06.001). doi.org/10.1038/s41380-020-00946-6). 189. Langan Y, Nashef L, Sander JW. Case-control study 197. Kishimoto T, Hagi K, Kurokawa S, Kane JM, of SUDEP. Neurology. 2005;64(7):1131–3 (https:// Correll CU. Long-acting injectable versus oral doi.org/10.1212/01.WNL.0000156352.61328.CB). antipsychotics for the maintenance treatment 190. Cheng ST, Zhang F. A comprehensive meta-review of schizophrenia: a systematic review and of systematic reviews and meta-analyses on comparative meta-analysis of randomised, nonpharmacological interventions for informal cohort, and pre–post studies. Lancet Psychiatry. dementia caregivers. BMC Geriatr. 2020;20(1):137 2021;8(5):387–404 (https://doi.org/10.1016/S2215- (https://doi.org/10.1186/s12877-020-01547-2). 0366(21)00039-0). 191. Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy 198. Schneider-Thoma J, Chalkou K, Dörries C, Bighelli M, Komossa K et al. Maintenance treatment with I, Ceraso A, Huhn M et al. Comparative efficacy and antipsychotic drugs for schizophrenia. Cochrane tolerability of 32 oral and long-acting injectable Database Syst Rev. 2020;(8):CD008016. antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic 192. Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis review and network meta-analysis. Lancet. D, Helfer B et al. Sixty years of placebo-controlled 2022;399(10327):824–36 (https://doi.org/10.1016/ antipsychotic drug trials in acute schizophrenia: S0140-6736(21)01997-8). systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J 199. Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Psychiatry. 2017;174(10):927–42 (https://doi. Bighelli I, Chaimani A et al. Efficacy, acceptability, org/10.1176/appi.ajp.2017.16121358). and tolerability of antipsychotics in children and adolescents with schizophrenia: a network 193. Schneider-Thoma J, Efthimiou O, Huhn M, Krause meta-analysis. Eur Neuropsychopharmacol. M, Reichelt L, Röder H et al. Second-generation 2018;28(6):659–74 (https://doi.org/10.1016/j. antipsychotic drugs and short-term mortality: euroneuro.2018.03.008). a systematic review and meta-analysis of placebo-controlled randomised controlled trials. 200. DelBello MP, Kadakia A, Heller V, Singh R, Hagi K, Lancet Psychiatry. 2018;5(8):653–63 (https://doi. Nosaka T et al. Systematic review and network org/10.1016/S2215-0366(18)30177-9). meta-analysis: efficacy and safety of second- generation antipsychotics in youths with bipolar 194. Kishi T, Ikuta T, Matsui Y, Inada K, Matsuda Y, depression. J Am Acad Child Adolesc Psychiatry. Mishima K et al. Effect of discontinuation v. 2022;61(2):243–54 (https://doi.org/10.1016/j. maintenance of antipsychotic medication on jaac.2021.03.021). relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis. Psychol Med. 2019;49(5):772–9 (https://doi.org/10.1017/ S0033291718001393). 127 Disorders: a systematic review. drug 16 october 2023)."
}